

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Institute on Minority Health and Health Disparities (NIMHD)
Funding Opportunity Title	NIMHD Basic and Applied Biomedical Research on Minority Health and Health Disparities (R01)
Activity Code	R01 Research Project Grant
Announcement Type	New
Related Notices	None
Funding Opportunity Announcement (FOA) Number	RFA-MD-12-004
Companion FOA	RFA-MD-12-003
Number of Applications	See Section III. 3. Additional Information on Eligibility .
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.307
FOA Purpose	<p>This funding opportunity announcement (FOA) is issued by the National Institute on Minority Health and Health Disparities (NIMHD) to solicit innovative grant applications on:</p> <ol style="list-style-type: none"> 1. Biological and genetic research to explore disease mechanisms or pathways that influence health outcomes in minority and health disparity populations.

	<p>2. Clinical and translational research linking basic science discovery with effective treatment or clinical practice.</p> <p>The overall goal of this initiative is to enhance our understanding of fundamental biological mechanisms involved in disease conditions and develop therapies or interventions that can directly or demonstrably contribute to the elimination of health disparities.</p> <p>Biological, genetic, clinical and translational research projects investigating the etiology, physiology, genetic risk factors, molecular pathways, gene-environmental interactions, pharmacogenomic and personalized medicine in health disparity populations are particularly encouraged.</p>
--	--

Key Dates

Posted Date	February 14, 2012
Open Date (Earliest Submission Date)	May 11, 2012
Letter of Intent Due Date	May11, 2012
Application Due Date(s)	June 11, 2012, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)	Not Applicable
Scientific Merit Review	September, 2012
Advisory Council Review	January, 2013
Earliest Start Date(s)	April, 2013
Expiration Date	June 12, 2012
Due Dates for E.O. 12372	Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the [SF 424 \(R&R\) Application Guide](#), except where instructed to do otherwise (in this FOA or in a Notice from the [NIH Guide for Grants and Contracts](#)). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in [Section IV](#). When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. **Applications that do not comply with these instructions may be delayed or not accepted for review.**

Apply for Grant Electronically

A compatible version of [Adobe Reader](#) is required for download. For Assistance downloading this or any Grants.gov application package, please contact Grants.gov Customer Support at <http://www07.grants.gov/contactus/contactus.jsp>.

Table of Contents

[Part 1. Overview Information](#)

[Part 2. Full Text of the Announcement](#)

[Section I. Funding Opportunity Description](#)

[Section II. Award Information](#)

[Section III. Eligibility Information](#)

[Section IV. Application and Submission Information](#)

[Section V. Application Review Information](#)

[Section VI. Award Administration Information](#)

[Section VII. Agency Contacts](#)

[Section VIII. Other Information](#)

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose/Research Objective

Racial and ethnic minorities (African Americans, Hispanics, Asian Americans, American Indian/Alaska Natives, Native Hawaiians and other Pacific Islanders) and other health disparity populations (rural and low income populations) experience a disproportionate burden of illness and disability in the United States. Striking differences in health outcomes related to obesity, infant mortality, cancer, coronary heart disease, hypertension, asthma, diabetes and HIV infection in these populations are well established. For example, infant morbidity and mortality risks are 2 to 3 fold higher among infants born to African American women compared to those born to non-Hispanic white women. Prevalence of asthma has risen in the US with highest rates observed among Puerto Rican Hispanics (18.4%) and non-Hispanic Blacks (14.6%) and remains a serious problem despite pharmacological

interventions. Furthermore, there is a considerable gap (~6 year difference) in life expectancy by race, with Caucasians having longer life expectancy than African Americans.

Complex interactions between social, cultural, biological, genetic and physical environments are implicated in health disparities but the mechanisms are not well understood. An understanding of fundamental biological and genetic contribution to disease is a critical component in developing therapies or treatment options for eliminating health disparities. Investigators are encouraged to conduct studies in a broad area of disease conditions associated with significant morbidity and mortality in health disparity populations with a focus on etiology, genetics, diagnosis, and intervention.

Investigators conducting Social, Behavioral, Health Services, and Policy Research on minority health or health disparities are directed to the related NIMHD FOA, [RFA-MD-12-003](#), *NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (RO1)*. Interdisciplinary research projects that include biological components as well as social, behavioral, health services or policy research components should make a determination about which FOA is more appropriate for the application.

Animal and in vitro studies are permitted if the work has an explicit link to minority health or health disparities (i.e., the work focuses on the specific susceptibility, disease progression, or treatment response for a particular health condition in one or more health disparity populations).

Note: Applications must articulate how the proposed work will specifically impact minority health or minimize health gaps between health disparity populations and the general population. Applications focused on diseases or conditions more prevalent or associated with greater morbidity/mortality in one or more disparity populations, without the proposed work itself being primarily focused on improving minority health or health disparities, are non-responsive to the FOA.

Specific Areas of Research Interest

Biological and Genetics Research

The NIH-supported research and advances in biological and genetic research have contributed to the development of drugs and therapies that improve health and prevent disease. Translation of these findings into improved health among health disparity populations remains a challenge. Potential biological mechanisms and pathways of disease conditions with significant mortality and burden of disease among these populations warrant investigation. Research topics that are relevant to this FOA include, but not limited to those listed below:

- Studies of health conditions not adequately studied in health disparity populations (i.e. Glomerular disease, scleroderma, neonatal asphyxia, autoimmune disorders, pancreatic disorders and traumatic brain injury).
- Investigation of biological/molecular basis of psychosocial stress, allostatic load and life course perspectives.

- Identification of genetic susceptibility to common and rare disease.
- Pharmacogenomic studies aimed at determining response to drugs and optimal dosing.
- Investigation of gene-environment interactions, epigenetic mechanisms of health disparities.
- Investigation of influences of gestational/prenatal physiology and its impact on health disparities later in life.
- Identification of rare genetic conditions among racial/ethnic minority populations.
- Development of bioinformatics tools and modeling approaches aimed at understanding genetic variation and susceptibility to disease among racial/ethnic minorities.
- Data analysis of existing genotype and phenotype data sets to identify novel loci of susceptibility.
- Development of modeling tools for systematic data mining and linking of existing data sets on minority populations

Clinical and Translational Research

Conduct of clinical trials and other clinical research studies in health disparity populations are vital in improving our understanding of the causes of many diseases that impact them. New insights or potential treatments gleaned from such studies can transform medical practice in targeted populations. Research topics that are relevant to this FOA include, but not limited to those listed below:

- Clinical and translational research on prospective biomarkers for disease diagnostics and prognosis in health disparity populations.
- Establishment of bio-repositories using specimens from health disparity populations.
- Development of novel technologies, diagnostic imaging and other diagnostic procedures in health disparity populations.
- Pilot studies, case controls studies, efficacy studies, RCTs to test existing pharmacological or other biologically-based treatments, interventions and/or novel interventions in health disparity populations.
- Methodology development for prevention, early detection, and treatment.

Section II. Award Information

Funding Instrument	Grant
Application Types Allowed	New The OER Glossary and the SF 424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards	NIMHD intends to commit an estimated \$2.0 million in FY 2013.

Award Budget	Although the size of award may vary with the scope of the project, the total direct costs are limited to \$250,000 annually.
Award Project Period	Scope of the proposed project should determine the project period. The maximum period is 5 years.

NIH grants policies as described in the [NIH Grants Policy Statement](#) will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions

Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

- Small Businesses
- For-Profit Organizations (Other than Small Businesses)

Governments

- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)

- Indian/Native American Tribal Governments (Other than Federally Recognized)
- U.S. Territory or Possession

Other

- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) **are not** eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations **are not** eligible to apply.

Foreign components, as [defined](#) in the NIH Grants Policy Statement, **are** allowed.

Required Registrations

Applicant organizations must complete the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.

- [Central Contractor Registration \(CCR\)](#) – must maintain an active registration, to be renewed at least annually
- [Grants.gov](#)
- [eRA Commons](#)

All Program Directors/Principal Investigators (PD(s)/PI(s)) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization.

All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least 4-6 weeks prior to the application due date.

Eligible Individuals (Program Director(s)/Principal Investigator(s))

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PD(s)/PI(s), visit the Multiple Program Director(s)/Principal Investigator(s) Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the [NIH Grants Policy Statement](#).

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.

Section IV. Application and Submission Information

1. Requesting an Application Package

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at [Grants.gov](#).

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the [SF424 \(R&R\) Application Guide](#), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit [Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications](#).

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in [Part 1. Overview Information](#), prospective applicants are asked to

submit a letter of intent that includes the following information:

- Descriptive title of proposed research
- Name, address, and telephone number of the PD(s)/PI(s)
- Names of other key personnel
- Participating institutions
- Number and title of this funding opportunity

The letter of intent should be sent to:

Robert Nettey, MD
Chief, Scientific Review Branch
Office of Extramural Research Administration
National Institute on Minority Health and Health Disparities
6707 Democracy Blvd., Suite 800, MSC 5465
Bethesda, MD 20892-5465
Telephone: (301) 496-3996
Fax: (301) 480-4049
Email: netteyr@mail.nih.gov

Required and Optional Components

The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.

Page Limitations

All page limitations described in the SF424 Application Guide and the [Table of Page Limits](#) must be followed.

PHS 398 Research Plan Component

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Specific Aims

The Specific Aims section should include a summary of the expected outcome(s) as they relate to the improvement of minority health and/or contribute to the elimination of health disparities. The Specific Aims section is limited to one page.

Resource Sharing Plan

Individuals are required to comply with the instructions for the Resource Sharing Plans

(Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the SF424 (R&R) Application Guide.

Appendix

Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

3. Submission Dates and Times

[Part I. Overview Information](#) contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications via [Grants.gov](#), the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the [eRA Commons](#), NIH's electronic system for grants administration.

Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

4. Intergovernmental Review (E.O. 12372)

This initiative is not subject to [intergovernmental review](#).

5. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement](#).

Pre-award costs are allowable only as described in the [NIH Grants Policy Statement](#).

6. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. [Section III. Eligibility Information](#) contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit [Applying Electronically](#).

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the Central Contractor Registration (CCR). Additional information may be found in the SF424 (R&R) Application Guide.

See [more tips](#) for avoiding common errors.

Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by [NIMHD](#), NIH. Applications that are incomplete and/or nonresponsive will not be reviewed.

Annual Meeting for Investigators

The PD/PI is expected to attend the annual NIMHD Grantees Meeting, held at or near NIH, Bethesda, MD. Co-Investigators or other members of the project team may also attend as warranted. Funds for travel to this meeting should be included in the budget request.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in [NOT-OD-10-115](#).

Section V. Application Review Information**1. Criteria**

Only the review criteria described below will be considered in the review process. As part of the [NIH mission](#), all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the project identify significant opportunity to advance knowledge and/or deepen our understanding of biological mechanisms or translation into clinical practice? Does the application provide an explicit and plausible link between the proposed work and minority health and/or health disparities? To what extent will the project have a direct and sizable effect on minority health and/or the elimination of health disparities?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD(s)/PI(s), do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?

If the project involves clinical research, are the plans for 1) protection of human subjects

from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the [Human Subjects Protection and Inclusion Guidelines](#).

Inclusion of Women, Minorities, and Children

When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the [Human Subjects Protection and Inclusion Guidelines](#).

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the

animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section](#).

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.

Applications from Foreign Organizations

Not Applicable.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) [Data Sharing Plan](#); 2) [Sharing Model Organisms](#); and 3) [Genome Wide Association Studies \(GWAS\)](#).

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMHD,, in accordance with [NIH peer review policy and procedures](#), using the stated [review criteria](#). Review assignments will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

- May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact/priority score.
- Will receive a written critique.

Appeals of initial peer review [will not be accepted for applications](#) submitted in response to this FOA.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Minority Health and Health Disparities. The following will be considered in making funding decisions:

- Scientific and technical merit of the proposed project as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD(s)/PI(s) will be able to access his or her Summary Statement (written critique) via the [eRA Commons](#).

Information regarding the disposition of applications is available in the [NIH Grants Policy Statement](#).

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the [NIH Grants Policy Statement](#).

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.

Awardees must comply with any funding restrictions described in [Section IV.5. Funding Restrictions](#). Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the [Award Conditions and Information for NIH Grants](#) website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the [NIH Grants Policy Statement](#) as part of the NoA. For these terms of award, see the [NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General](#) and [Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities](#). More information is provided at [Award Conditions and Information for NIH Grants](#).

Cooperative Agreement Terms and Conditions of Award

Not Applicable.

3. Reporting

When multiple years are involved, awardees will be required to submit the [Non-Competing Continuation Grant Progress Report \(PHS 2590\)](#) annually and financial statements as required in the [NIH Grants Policy Statement](#).

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the [NIH Grants Policy Statement](#).

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to

report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over \$25,000. See the [NIH Grants Policy Statement](#) for additional information on this reporting requirement.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

[Grants.gov Customer Support](#) (Questions regarding Grants.gov registration and submission, downloading or navigating forms)

Contact Center Phone: 800-518-4726

Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)

Telephone 301-435-0714

TTY 301-451-5936

Email: GrantsInfo@nih.gov

eRA Commons Help Desk (Questions regarding eRA Commons registration, tracking application status, post submission issues)

Phone: 301-402-7469 or 866-504-9552 (Toll Free)

TTY: 301-451-5939

Email: commons@od.nih.gov

Scientific/Research Contact(s)

Nishadi Rajapakse, PhD, MHS

Health Scientist Administrator

Division of Scientific Programs

National Institute on Minority Health and Health Disparities (NIMHD)

6707 Democracy Blvd, Suite 800

Bethesda, MD 20892-5465

Telephone: 301-496-4338

Email: chandima.rajapakse@nih.gov

Peer Review Contact(s)

Robert Nettey, MD

Chief, Scientific Review Branch

Office of Extramural Research Administration

National Institute on Minority Health and Health Disparities (NIMHD)

6707 Democracy Blvd, Suite 800

Bethesda, MD 20892-5465

Telephone: (301) 496-3996
Email: netteyr@mail.nih.gov

Financial/Grants Management Contact(s)

Priscilla Grant, JD, CRA
Chief Grants Management Officer
Office of Extramural Research Administration
National Institute on Minority Health and Health Disparities (NIMHD)
6707 Democracy Blvd, Suite 800
Bethesda, MD 20892-5465
Telephone: 301-594-8412
Email: grantp@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH [policy notices](#) may affect your application submission. A full list of policy notices published by NIH is provided in the [NIH Guide for Grants and Contracts](#). All awards are subject to the terms and conditions, cost principles, and other considerations described in the [NIH Grants Policy Statement](#).

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.

[Weekly TOC for this Announcement](#)
[NIH Funding Opportunities and Notices](#)



Office of
Extramural
Research
(OER)



National
Institutes of
Health
(NIH)
9000
Rockville
Pike
Bethesda,
Maryland
20892



Department
of Health
and Human
Services
(HHS)



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files,

see [Help Downloading Files.](#)